interleukin-1 — LLMpedia

Contents

interleukin-1 is a proinflammatory cytokine family central to innate immunity and inflammatory responses. First characterized during studies at institutions such as National Institutes of Health, Harvard University, and University of California, San Francisco, the family has been implicated in host defense, fever, and coordination of immune cell networks involving players like Centers for Disease Control and Prevention, World Health Organization, and clinical centers including Mayo Clinic and Johns Hopkins Hospital.

Structure and isoforms

The interleukin-1 family comprises multiple protein products encoded by genes located on chromosome 2 and studied in laboratories at Massachusetts Institute of Technology, Stanford University, and Cold Spring Harbor Laboratory. Major isoforms include IL-1α and IL-1β, along with receptor antagonist forms encoded by IL1RN; structural determination efforts involved facilities such as European Molecular Biology Laboratory and Max Planck Society. High-resolution structures were resolved using techniques developed at Brookhaven National Laboratory and Argonne National Laboratory, and publications in journals associated with Nature Publishing Group, Cell Press, and Proceedings of the National Academy of Sciences detailed tertiary arrangements, cleavage sites, and propeptide regions. Comparative genomics linking to work at University of Cambridge and University of Oxford revealed conserved β-trefoil folds, post-translational processing by caspases characterized at The Rockefeller University, and isoform-specific receptor affinities investigated by researchers from Yale University and University College London.

Interleukin-1 isoforms signal through receptors that couple to adaptor proteins such as MyD88 and IRAK, pathways explored in collaborations involving National Cancer Institute and Institut Pasteur. Signaling cascades activate transcription factors including NF-κB and AP-1, with discoveries attributed to groups at University of Pennsylvania, Columbia University, and University of Chicago. IL-1-driven responses orchestrate leukocyte recruitment studied in clinical settings like Cleveland Clinic and Mount Sinai Health System, promote fever via hypothalamic circuits investigated at University of California, Los Angeles and University of Michigan, and enhance acute-phase reactions cataloged by investigators from Imperial College London and Karolinska Institutet. Cross-talk with tumor necrosis factor pathways studied at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center illustrates integration with adaptive responses characterized by teams at University of Toronto and Vanderbilt University.

Expression of interleukin-1 genes is regulated by transcriptional networks elucidated in studies at Salk Institute, Scripps Research, and John Innes Centre. Inducers include pathogen-associated signals recognized by toll-like receptors researched at Pasteur Institute, Johns Hopkins Bloomberg School of Public Health, and London School of Hygiene & Tropical Medicine, with chromatin remodeling and epigenetic control described by laboratories at Broad Institute and Wellcome Trust Sanger Institute. Post-translational regulation involves inflammasomes assembled with NLRP3 components whose characterization involved investigators from University of Bonn, Harvard Medical School, and University of Freiburg. Negative regulation by IL-1 receptor antagonist and soluble receptors was defined in clinical trials at Brigham and Women's Hospital and translational programs at Imperial College Healthcare NHS Trust.

Dysregulated interleukin-1 activity contributes to autoinflammatory syndromes first delineated by clinicians at Great Ormond Street Hospital and Royal Free Hospital, and to chronic conditions studied at Karolinska University Hospital and St Thomas' Hospital. Elevated signaling is implicated in rheumatoid arthritis cohorts evaluated at Hospital for Special Surgery and Guy's and St Thomas' NHS Foundation Trust, in atherosclerosis research from Framingham Heart Study collaborators, and in neuroinflammation contexts investigated at Mayo Clinic Arizona and Massachusetts General Hospital. Roles in sepsis were examined through multicenter trials coordinated by National Institutes of Health networks and European Society of Intensive Care Medicine, while cancer-associated inflammation linking to tumor progression was explored by teams at MD Anderson Cancer Center and Cancer Research UK. Genetic variants affecting IL1 pathways were reported in population studies including those by UK Biobank and Framingham Heart Study.

Targeting interleukin-1 signaling has produced therapies developed by pharmaceutical companies collaborating with academic centers such as University of California, San Diego and regulatory review by agencies like Food and Drug Administration and European Medicines Agency. Agents include receptor antagonists, monoclonal antibodies, and small molecules trialed at Cleveland Clinic Lerner College of Medicine and National Heart, Lung, and Blood Institute-sponsored studies. Clinical applications encompass treatment of autoinflammatory conditions, gout flares managed in trials at Johns Hopkins University School of Medicine, and adjunctive use in cardiovascular disease trials conducted by Framingham Heart Study investigators. Ongoing translational research partnerships involve Bill & Melinda Gates Foundation, biotech firms, and consortia such as Human Genome Project-derived networks to advance personalized approaches and biomarkers validated by groups at European Molecular Biology Organization and Wellcome Trust.

Category:Cytokines